Skip to main content
Porton Pharma Solutions Ltd. logo

Porton Pharma Solutions Ltd. — Investor Relations & Filings

Ticker · 300363 ISIN · CNE100001S57 LEI · 300300IQTJFHA0YRXE68 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,163 across all filing types
Latest filing 2024-12-10 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300363

About Porton Pharma Solutions Ltd.

https://www.porton.cn

Porton Pharma Solutions Ltd. is a global contract development and manufacturing organization (CDMO) providing end-to-end solutions for the pharmaceutical and biotechnology sectors. The company specializes in the development and manufacturing of small molecule APIs, intermediates, and drug products, while expanding its capabilities into biologics and cell and gene therapies. Its service portfolio encompasses process research and development, analytical services, pilot-scale production, and large-scale commercial manufacturing. Porton operates a network of R&D centers and manufacturing facilities designed to meet international regulatory standards, including those of the FDA and EMA. By leveraging an integrated technology platform, the company supports clients throughout the entire drug lifecycle, from preclinical development to commercialization, focusing on operational excellence and supply chain security.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于重庆博腾制药科技股份有限公司部分募集资金投资项目结项并将节余募集资金永久补充流动资金的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from a sponsoring institution (中信证券股份有限公司) regarding the completion of certain fundraising investment projects and the permanent supplementation of surplus raised funds into working capital for 重庆博腾制药科技股份有限公司. It includes specific financial figures about the raised funds, usage, balances, project completion status, and approvals from the board, supervisory committee, and sponsor institution. The document references regulatory requirements and approvals, and it is a formal verification and opinion report on the use of raised funds. It is not an announcement of a report publication, nor a brief summary or presentation. It is not a certification or a voting result announcement. The content is focused on the audit and verification of fundraising usage and compliance, which aligns with the definition of an Audit Report / Information (AR). The document length is 4179 characters, which is substantial and contains detailed financial and procedural information, not just a short announcement. Therefore, the best classification is AR (Audit Report / Information).
2024-12-10 Chinese
中信证券股份有限公司关于重庆博腾制药科技股份有限公司拟变更部分募集资金用途的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from a sponsoring institution (中信证券股份有限公司) regarding a proposed change in the use of raised funds by 重庆博腾制药科技股份有限公司. It references regulatory guidelines related to securities issuance and fundraising management, details the original fundraising amounts, usage, and the proposed reallocation of unused funds to permanent working capital. The document includes board and supervisory committee meeting approvals and the sponsor's verification opinion. It is not a full financial report but a regulatory compliance and verification document related to fundraising use changes. The document length is 4402 characters, which is relatively short but contains substantive content about fundraising use changes and approvals, not merely an announcement or certification. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes.
2024-12-10 Chinese
第五届监事会第二十一次临时会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a supervisory board meeting of Chongqing Boteng Pharmaceutical Technology Co., Ltd. It details decisions regarding the use of surplus raised funds and changes in the use of some raised funds. The document includes voting results and mentions that these resolutions will be submitted to the upcoming shareholders' meeting for approval. It references regulatory compliance with Shenzhen Stock Exchange rules and includes opinions from the sponsoring institution (CITIC Securities). The document is an announcement of meeting resolutions and related decisions, not a full financial report or detailed management discussion. It does not contain financial statements or detailed financial analysis. The document length is short (1538 characters), and it serves as a formal disclosure of board/supervisory committee decisions. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or senior management bodies.
2024-12-10 Chinese
第五届董事会第二十九次临时会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at a board of directors meeting of Chongqing Boteng Pharmaceutical Technology Co., Ltd. It details decisions such as the nomination of a new director, approval of changes in the use of raised funds, and the scheduling of an upcoming extraordinary shareholders meeting. The document references compliance with stock exchange listing rules and mentions that these resolutions will be submitted to the shareholders' meeting for approval. It does not contain financial statements or detailed financial data but rather reports on board decisions and corporate governance matters. Therefore, it fits the category of Board/Management Information (MANG). The document length is short (2114 characters), and it is not a report publication announcement or certification. Hence, the classification is MANG with high confidence.
2024-12-10 Chinese
关于召开2024年第一次临时股东大会的通知
AGM Information Classification · 100% confidence The document is a detailed notice about convening the 2024 first extraordinary general meeting of shareholders for Chongqing Porton Pharmaceutical Technology Co., Ltd. It includes information about the meeting date, agenda proposals, voting procedures (both onsite and online), registration details, and attachments such as proxy forms and voting instructions. There is no financial data or report content, but rather a formal announcement and instructions related to a shareholders' meeting. This fits the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings. The document length is 4640 characters, which is consistent with a meeting notice rather than a full report. Therefore, the correct classification is AGM Information (AGM-R).
2024-12-10 Chinese
关于拟变更部分募集资金用途的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the proposed change in the use of part of the company's raised funds. It details the original fundraising, the amount used, the remaining balance, and the decision to reallocate unused funds from a specific project to permanent working capital. It includes approvals from the board and supervisory committee and mentions that the change will be submitted to the shareholders' meeting for approval. The document is a formal disclosure about changes in the use of capital raised through a non-public stock issuance, which fits the category of Capital/Financing Update (CAP). The document length is 4030 characters, which is sufficient to contain substantive information rather than just a brief announcement or a report publication notice. Therefore, it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). It is not an Annual Report, Interim Report, or Earnings Release as it does not contain financial statements or results but focuses on fundraising use changes. Hence, the correct classification is CAP with high confidence.
2024-12-10 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.